Which Dog Breed Best Fits Your Lifestyle? Here's What the Experts Say
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The right dog can bring joy and adventure into your life, but each breed is different—and choosing the one that fits into your routine can make all the difference.
Some dogs need plenty of space, while others thrive in cozy apartments; some may need constant activities, while others may prefer a calmer environment. But there's one breed that seems to be more versatile than others, the golden retriever.
Golden retrievers are loyal and devoted companions, says the American Kennel Club (AKC), and their inclination to please their owners makes them a highly adaptable and trainable breed.
Golden retriever
Dr. Carly Fox senior veterinarian in the emergency and urgent care service at the Schwarzman Animal Medical Center told Newsweek that golden retrievers are "the quintessential dog," and "man's best friend to the end."
She explains that these dogs are fairly adaptable to different lifestyles, and emotionally in tune with their owners. Ideally, they should receive one or two hours of exercise a day, be around people often, and have several avenues for mental stimulation, like obedience training, puzzles, or scent work.
However, she added that goldens can develop significant orthopedic disease if overweight, so keeping them slim is a must.
"For these reasons, I would place them in the 'versatile' category to moderately active lifestyle", she said.
The AKC says that as intelligent and affectionate companions golden retrievers make great pets for families with children. Like any breed, early socialization and puppy training are important for their development.
Giving them enough exercise and mental stimulation can help prevent misbehavior. While they can make excellent companions on long runs, hikes, and bike rides, they also thrive in calmer spaces, as long as they get their daily walks.
A stock image shows a golden retriever on a walk in the woods with its owner.
A stock image shows a golden retriever on a walk in the woods with its owner.
getty images
Other easily adaptable dog breeds
Other easily adaptable dogs, according to Dr. Todd East, veterinary affairs director, Royal Canin North America, include Labrador retrievers and poodles.
He told Newsweek that you are equally likely to find a Labrador retriever jumping off a dock, as you are curled up at your feed snoring.
"These dogs are used in a variety of jobs from hunting to service. Their drive to please is unmatched in the breed world, which makes them one of the most adaptable breeds out there."
As for poodles, he explains that besides being fairly versatile, they also have the added benefit of being less allergenic than other breeds.
"The poodle is one of my favorite patients from a veterinary point of view, especially the standards, due to their calm demeanor, heightened intelligence and just being easy to examine. They have high trainability, making them an adaptable breed."
Mix-breed dogs, also make pretty adaptable breeds, and are able to thrive in a variety of diverse environments.
Dogs that fit in your active lifestyle
If you lead an active lifestyle, you may want to look for dog breeds that are more in tune with your needs.
Dr. Ashly Smith, veterinarian at Small Door Veterinary told Newsweek that in this case, breeds like Border Collies, Australian Shepherds, and Vizslas are probably the most well-suited for you.
"These breeds were originally developed for work like herding or hunting, so they have high energy levels, sharp intelligence, and a need for regular physical and mental stimulation.
"Without adequate exercise, they can become bored or develop behavioral issues. They thrive in homes where daily runs, hikes, or advanced training are part of the routine," she said.
East added that breeds like German shepherds, often employed by the military or the police for their impressive stature and intelligence, and German short-haired pointers, which were originally bred for sport, can also make a great addition to an active lifestyle.
Dogs that thrive in a more relaxed environment
If you're specifically looking for the "couch potato" type of canine companion, Bulldogs, both English and French, according to East, will definitely make worthy candidates.
"Based on their short legs, stocky stature and a short muzzle with tiny nostrils, these dogs are not physically built for an active lifestyle. These breeds would rather be curled up next to you on the couch than outside chasing squirrels", he said.
Despite their size, Mastiffs are also a laid-back breed who enjoy spending time chilling at home with their owners. If you are looking for a dog that is on the smaller side, a pug would also make a great choice.
"These dogs are perfect for the lap, so long as you can deal with a bit of snoring", East added.
Basset Hounds and Cavalier King Charles Spaniels are a great match for a more chilled lifestyle, according to Smith.
"These dogs tend to have lower energy requirements and are content with shorter walks and lots of cuddle time", she said.
"That said, 'lazy' doesn't mean no exercise. These dogs still benefit from regular activity to maintain a healthy weight and prevent joint problems, especially if they are prone to orthopedic issues."
Do you have funny and adorable videos or pictures of your pet you want to share? Send them to life@newsweek.com with some details about your best friend and they could appear in our Pet of the Week lineup.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
9 hours ago
- Newsweek
Map Shows Countries Where US Has Issued Fresh Travel Warnings
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. has issued new travel warnings in response to disease outbreaks in several countries, warning Americans to "practice enhanced precautions" when visiting the affected regions. On August 4, Centers for Disease Control and Prevention (CDC) issued a level 2 travel alert, part of its four-tier system, over global polio in several countries. Travelers are advised to make sure they are up to date with their polio vaccines. Anyone visiting the affected countries who previously completed the full, routine polio vaccine series may also receive a single, lifetime booster dose of polio vaccine. The list of affected countries includes Afghanistan, Algeria, Angola, Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Côte d'Ivoire (Ivory Coast), Democratic Republic of the Congo, Djibouti, Egypt, Ethiopia, Finland, French Guiana (France), Germany, Ghana, Guinea, Indonesia, Israel, the West Bank and Gaza, Kenya, Liberia, Niger, Nigeria, Pakistan, Papua New Guinea, Poland, Republic of South Sudan, Senegal, Sierra Leone, Somalia, Spain, Sudan, Tanzania, including Zanzibar, Uganda, United Kingdom, including England, Scotland, Wales, and Northern Ireland, Yemen and Zimbabwe. In the past month, the CDC also raised Level 2 travel alerts over outbreaks of chikungunya in China, confirmed and suspected cases of diphtheria in Guinea, and outbreaks of mpox in Liberia and Sierra Leone. The CDC ranks travel alerts from Level 1 ("Practice Usual Precautions") to Level 4 ("Avoid All Travel"). Level 2 urges travelers to take stronger precautions due to an elevated risk of infection. Why It Matters These advisories underscore the importance of Americans staying informed about health and safety risks when traveling overseas. Conditions such as mpox and diphtheria can worsen quickly if not managed properly. What To Know Chikungunya in China On August 1, the CDC issued a Level 2 travel alert for Guangdong Province, China, citing an outbreak of chikungunya, a mosquito-borne virus. Most cases have been reported in Foshan city. The disease is spread through mosquito bites and can cause fever, joint pain, headache, muscle pain, joint swelling or a rash. The CDC recommends two approved vaccines for those traveling to affected areas and encourages mosquito bite prevention measures, such as using insect repellent; wearing long-sleeved shirts and pants; and staying in places with air conditioning or that have screens on the windows and doors. Pregnant travelers are advised to reconsider travel to affected areas. Diphtheria in Guinea On July 22, the CDC announced a Level 2 travel alert for the Kankan region in Guinea due to confirmed and suspected cases of diphtheria. The CDC said vaccination against diphtheria was essential to protect against disease, urging travelers to ensure they are up to date on immunizations. Diphtheria symptoms include fever, sore throat, difficulty swallowing, change in voice, shortness of breath, weakness, or fatigue. The CDC advises travelers to avoid contact with people displaying symptoms. Clade II Mpox in Liberia and Sierra Leone The CDC issued another Level 2 alert on July 22 for Liberia and Sierra Leone due to outbreaks of clade II mpox. "Unlike the ongoing global clade II mpox outbreak that began in 2022, which has primarily affected gay, bisexual, and other men who have sex with men (MSM), these outbreaks have affected males and females approximately equally," said the alert. Transmission is occurring through close contact, including through sexual or other intimate contact. The CDC recommends travelers who anticipate intimate or sexual contact in affected areas are vaccinated. The CDC advises travelers to avoid contact with people who are sick with signs and symptoms of mpox, including those with skin or genital lesions. Those who develop new, unexplained skin rashes (lesions on any part of the body), with or without fever and chills, should seek immediate medical care. What Happens Next The CDC will continue tracking global outbreaks and will update its travel health notices as new information becomes available throughout the year.
Newsweek
10 hours ago
- Newsweek
Map Shows States Where People Told To Monitor for Coughs, Chest Tightness
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Millions of residents across three states were asked to monitor themselves for health symptoms such as coughing and chest tightness on Monday as poor air quality persisted. Why It Matters Large areas of Maine, Michigan and Vermont faced elevated air pollution levels on Monday, prompting state agencies to issue air quality alerts and health advisories. The warnings, spurred by smoke from ongoing Canadian wildfires, emphasized risks for sensitive groups such as children, the elderly, and those with pre-existing health conditions. The alerts highlighted broader concerns about the impact of wildfire smoke on public health across the U.S. Northeast and Midwest, as similar conditions have become a frequent occurrence this summer due to wildfire patterns. What To Know The Maine Department of Environmental Protection's Bureau of Air Quality issued an alert for particle pollution across the state until 11 p.m. EDT on Monday. The alert covered areas including Oxford, Franklin, Somerset, York, Cumberland, Androscoggin, Kennebec, Waldo and several coastal counties. Officials warned that particle pollution levels were expected to be in the "Unhealthy for Sensitive Groups" range, and recommended people limit strenuous outdoor activity to reduce the risk of adverse health effects. The very young, elderly, people with respiratory conditions such as asthma and heart disease, and those who work hard outdoors, were mentioned as especially vulnerable. Residents experiencing symptoms such as shortness of breath, coughing, throat irritation or chest discomfort were advised to decrease the intensity and duration of outdoor activities. A stock photo shows a man experiencing chest tightness. A stock photo shows a man experiencing chest tightness. Motortion/Getty Similarly, the Michigan Department of Environment, Great Lakes and Energy declared an Air Quality Advisory for Monday across the state, spanning Midland, Bay, Huron, Saginaw, Tuscola, Genesee, Oakland, Washtenaw, Wayne and more. Fine particulate matter (PM2.5) levels were projected to reach "Unhealthy for Sensitive Groups" range, with some locations forecasted to hit the "Unhealthy" range. The advisory urged everyone—particularly those with heart or respiratory illnesses—to avoid strenuous outdoor activities and monitor for symptoms like coughing, chest tightness or wheezing. Additional guidance included keeping windows closed, using filtered air systems and limiting activities contributing to outdoor air pollution such as burning wood. In Vermont, the Vermont Agency of Natural Resources issued an Air Quality Health Advisory warning of fine particulates to hit the Unhealthy for Sensitive Groups range on Monday for Eastern Addison, Eastern Rutland, Eastern Windsor, Orange, Western Addison, Western Rutland and Western Windsor counties in effect through midnight. "Sensitive groups should reduce prolonged or heavy exertion," the alert said. "It's okay to be active outside, but take more breaks and do less intense activities. Watch for symptoms such as coughing or shortness of breath." Several other states across the Upper Midwest and Northeast also had air quality alerts in place, although the alerts didn't specify that people should monitor themselves for symptoms such as coughing or chest tightness. What People Are Saying National Weather Service meteorologist John Boris at the Gaylord, Michigan, office told Newsweek: "Right now, our biggest issue is the fact that there really isn't a whole lot of we get a little bit more flow, there's probably a couple more days of us dealing with this, at least in Michigan." An air quality alert issued in Michigan: "It is recommended that, when possible, you avoid strenuous outdoor activities, especially those with heart disease and respiratory diseases like asthma. Monitor for symptoms such as wheezing, coughing, chest tightness, dizziness, or burning in nose, throat, and eyes." What Happens Next The advisories in Maine, Michigan and Vermont were expected to remain in effect through Monday night, with potential for extension depending on smoke migration and weather conditions. Officials continue to urge residents to track air quality forecasts through official resources, heed recommendations for health precautions, and reduce activities—such as open burning—that exacerbate air pollution.
Newsweek
10 hours ago
- Newsweek
PTSD Drug Discovery May Help Patients Let Go of Trauma
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A promising new drug could help people living with post-traumatic stress disorder (PTSD) finally let go of trauma. This is the discovery of scientists at the Institute of Basic Science (IBS) and Ewha Womans University in South Korea who have identified a new brain mechanism driving the mental health condition—and a drug with the potential to counteract its effects. The team has shown for the first time that "excessive" gamma-aminobutyric acid (GABA)—the brain's primary neurotransmitter—produced by star-shaped support cells in the brain known as "astrocytes" impairs the brain's ability to extinguish fear memories. This inability to forget traumatic memories even after a long period of time is distinct to PTSD and has posed a major hurdle for treatment. Current medications targeting serotonin receptors offer limited relief for only a subset of patients, the authors said. "Current FDA-approved treatments for PTSD are mainly SSRIs, which focus on reducing general symptoms like anxiety and mood instability," study author Dr. Woojin Won told Newsweek. "However, only about 20–30 percent of patients achieve full remission, which is often unsatisfactory. Our approach is fundamentally different." Woman with head in hands in dark room. Woman with head in hands in dark room. Domepitipat/Getty Images Won continued: "While prefrontal cortex (PFC) dysfunction has been consistently reported in PTSD, the role of GABAergic mechanisms in this dysfunction has not been fully explored." The researchers found that a brain-permeable drug called KDS2010, which selectively blocks an enzyme called 'monoamine oxidase B' (MAOB) responsible for this abnormal GABA production, can reverse PTSD-like symptoms in mice. "It targets the pathological reactive astrocyte-derived GABA at the source," said Won. "Unlike traditional MAO inhibitors, which can have off-target effects and are irreversible, KDS2010 is highly selective, reversible, and brain-penetrant, making it safer and more targeted." They report the drug has already passed Phase 1 safety trials in humans, which makes it a "strong candidate" for future PTSD treatments. GABA can be a positive thing, helping to regulate motor function, sensory processing and emotional stability. It can also offer calming effects, including helping to reduce anxiety and stress by controlling overactive neurons. "However," Won explained, "GABA does not act uniformly across the brain, and its outcome varies depending on the target circuit. "While GABA is generally calming, in this context [of the researcher's findings], it was silencing a circuit that the brain needs to overcome fear. This highlights that the effect of GABA is not simply good or bad, but it critically depends on where it acts and what neural circuits are involved." Digital illustration showing brain waves and activity. Digital illustration showing brain waves and activity. selvanegra/Getty Images The study focused on the medial prefrontal cortex (mPFC), a region of the brain critical for regulating fear. It found that PTSD patients had unusually high levels of GABA and reduced cerebral blood flow in this area, based on brain imaging studies of more than 380 participants. On the other hand, GABA levels decreased in patients who showed clinical improvement, suggesting the chemical has a central role in recovery. To unearth the origin of the excess GABA, the researchers examined postmortem human brain tissue and used PTSD-like mouse models. They discovered that astrocytes, not neurons, were producing abnormal amounts of GABA via the MAOB enzyme. This astrocyte-derived GABA impaired neural activity, blocking the brain's ability to forget traumatic memories. "This inspired us to investigate astrocytic GABA dysregulation as a potential driver of PTSD pathology, and ultimately, as a novel therapeutic target," said Won. Explaining further how "excessive" GABA in PTSD is produced, he added: "Trauma and stress might increase putrescine metabolism, which raises the levels of MAOB's presubstrate, leading to more GABA production. "At the same time, the enzyme that breaks down GABA, ABAT, is reduced. Together, this combination causes the accumulation of astrocytic GABA and excessive tonic inhibition in key brain regions like the PFC." When the team administered KDS2010, "a highly selective, reversible MAOB inhibitor" developed at IBS, the mice showed normalized brain activity and were able to extinguish fear responses. The promising drug reduced GABA levels, restored blood flow in the mPFC, and re-enabled memory extinction mechanisms. This confirms astrocytic MAOB as a central driver of PTSD symptoms and MAOB inhibition as a viable therapeutic path. The researchers flagged a major challenge of the study was linking clinical findings in humans with cellular mechanisms in the lab. They addressed this by applying a "reverse translational" strategy, beginning with clinical brain scans and moving backward to identify the cellular source of dysfunction. They then confirmed the mechanism and tested drug effects in animal models. This led to a new understanding of how glial cells—non-neuronal cells long thought to be passive—actively shape psychiatric symptoms. Would this type of drug be used alongside other methods like talking therapy for PTSD? "DS2010 alone has a strong potential to restore brain function by normalizing astrocytic GABA and improving fear extinction. However, we think that combining it with psychotherapy, especially exposure-based therapy, could create even greater synergy. By reducing abnormal inhibition in fear extinction circuits, KDS2010 may help the brain become more responsive to therapeutic input," Won explained. How would it be administered? "KDS2010 is an orally available small molecule. In preclinical and early-phase clinical studies, it has been administered once daily in capsule or liquid form. This makes it highly feasible for long-term outpatient use, similar to antidepressants." What about side effects? "In the Phase 1 clinical trial, KDS2010 was found to be well tolerated, with no serious adverse effects reported, even at higher doses. This safety is largely due to its selectivity for MAOB and its reversible mechanism, which avoids the long-term enzyme compensation seen with older MAO inhibitors. Nevertheless, larger trials in PTSD patients will be needed to fully assess tolerability and any rare side effects." Won said the drug is currently undergoing Phase 2 trials for other neurological disorders, which means its safety profile is already being tested extensively in patients. "Because of this, we believe it could reach the public faster than many other new drugs. If future trials for PTSD are successful and regulatory steps proceed smoothly, it could become available within a few years. Importantly, KDS2010 is part of a broader platform that may also be useful for treating other disorders involving astrocytic dysfunction, such as Parkinson's and Alzheimer's disease." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about PTSD? Let us know via health@ Reference Yoon, S., Won, W., Lee, S., Han, K., Ha, E., Lee, J., Hyeon, S. J., Joo, Y., Hong, H., Lee, H., Song, Y., Park, K. D., Huber, B. R., Lee, J., Edden, R. A. E., Suh, M., Ryu, H., Lee, C. J., & Lyoo, I. K. (2025). Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder. Signal Transduction and Targeted Therapy, 10(1), 240.
